Alzamend Neuro (ALZN) Interest Coverage Ratio Growth (1y) (2021 - 2026)
Powered by 
Analysis
Alzamend Neuro (ALZN) Interest Coverage Ratio Growth (1y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 209.94 Bn | 195.95 Bn | 7.24 Bn | 36.43% |
| 2 | Gilead Sciences | 179.74 Bn | 176.57 Bn | 6.22 Bn | -532.04% |
| 3 | Vertex Pharmaceuticals | 132.05 Bn | 124.20 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.43 Bn | 74.44 Bn | 3.93 Bn | -60.78% |
| 5 | Argenx Se | 61.23 Bn | 56.04 Bn | 1.37 Bn | 176.09% |
| 6 | Moderna | 53.42 Bn | 48.28 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.77 Bn | 30.47 Bn | 992.69 Mn | 1,170.12% |
| 8 | Biogen | 31.62 Bn | 30.33 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Alzamend Neuro | 5.57 Mn | 5.57 Mn | - | -755.35% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Apr 30, 2026 | -755.35% |
| Jan 31, 2026 | -219.90% |
| Oct 31, 2025 | 3.03% |
| Jul 31, 2025 | -1,256.63% |
| Apr 30, 2025 | -285.63% |
| Jan 31, 2025 | 51.94% |
| Oct 31, 2024 | 42.27% |
| Jul 31, 2024 | 95.83% |
| Apr 30, 2024 | 90.89% |
| Jan 31, 2024 | 59.35% |
| Oct 31, 2023 | 22.26% |
| Jul 31, 2023 | 3.02% |
| Apr 30, 2023 | 1.01% |
| Jan 31, 2023 | -1,576.86% |
| Oct 31, 2022 | -286.39% |
| Jul 31, 2022 | -1,070.86% |
| Apr 30, 2022 | -17,955.54% |
| Jan 31, 2022 | -706.53% |
| Oct 31, 2021 | -774.62% |
| Jul 31, 2021 | 98.06% |